| Literature DB >> 35592535 |
AlHanouf AlHabdan1, Fatemah AlAhmari2.
Abstract
Purpose: To assess the efficacy of Er,Cr:YSGG lasers in reducing dentine hypersensitivity (DH).Entities:
Keywords: Er,Cr:YSGG laser; dentine hypersensitivity; dentine sensitivity; phototherapy
Year: 2022 PMID: 35592535 PMCID: PMC9113032 DOI: 10.2147/IJGM.S355890
Source DB: PubMed Journal: Int J Gen Med ISSN: 1178-7074
Figure 1PRISMA flowchart of the search strategy.
General Characteristics of the Studies That Were Included in the Review
| Author/Year | Place | Number of Subjects | Number of Teeth | Study Design | Stimulus | Mean Difference of Pain Assessment Scores Between Baseline and Follow‐Up | Percentage of DH Reduction Between Baseline and Final Follow-Up | Adverse Effects | |
|---|---|---|---|---|---|---|---|---|---|
| Moeintaghavi et al | Iran | 24 | NR | PD | G 1: InGaAlP and GaAIAS laser (200mW) | Air stimulus | −1.1 | −17% | No |
| G 2: Er,Cr,YSGG (Two applications 15 min apart 0.25 W & 0.5 W) | −4.33 | −55% | |||||||
| G 3: fluoride varnish | −2.1 | −29.1% | |||||||
| G 4: low level laser therapy without emisson | 1 | 14% | |||||||
| Aranha and de Paula Eduardo | Brazil | 28 | 7 | PD | G 1: control | Air stimulation and pressure | 0.56 | 29% | NR |
| 7 | G 2: Er:YAG (0.64 W. 5.9 J/cm2) | 0.22 | 22% | ||||||
| 7 | G 3: Er,Cr:YSGG (0.25W, 4.4 J/cm2) | 0.69 | 43.9% | ||||||
| −0.2 | −10% | ||||||||
| 7 | G 4: Er,Cr:YSGG (0.5W, 8.9J/cm2) | ||||||||
| Ozlem et al | Turkey | 17 | 100 | PD | G 1: gluma desensitizer (GCA) | Precalibrated Yeable probe | 28.65 | 191% | No |
| G 2: Nd:YAG (1W/cm2, 4.4 J/cm2) | 44.4 | 319% | |||||||
| G 3: gluma desensitizer (GCA) followed by Nd:YAG (1W/cm2, 4.4 J/cm2) | 51.9 | 411% | |||||||
| G 4: Er,Cr:YSGG (0.25W, 4.4 J/cm2) | 71.3 | 472% | |||||||
| G 5: gluma desensitizer (GCA) followed by Er,Cr:YSGG (0.25 W, 4.4 J/cm2) | 72 | 660% | |||||||
| Pourshahidi et al | Iran | 17 | 34 | PD | G 1: Diode laser (940nm) | Air spray with pressure of 45–60 psi for 35s from 2 mm distance and an explorer | −5.33 | −65% | NR |
| G 2: Er,Cr:YSGG (0.25W, 4.4 J/cm2) | −6.41 | −79% | |||||||
| Yilmaz et al | USA | 42 | 146 | SM | G 1: Er,Cr:YSGG used without emission (control) | Air stimulus | −0.79 | −11.4% | No |
| G 2: Er,Cr:YSGG (0.25W, 4.4 J/cm2) | −5.67 | −80.7% | |||||||
| Yilmaz et al | USA | 51 | 174 | SM | Control (no treatment) | Air stimulus | −0.5 | −7.2% | No |
| Er,Cr:YSGG (0.25 W, 4.4 J/cm2) | −6.2 | −86.1% | |||||||
| GaAlAs diode laser (810nm, 8.5 J/cm2) | −6 | −84.5% | |||||||
| Yilmaz and Bayindir | USA | 20 | 60 | SM | G 1: Er,Cr:YSGG used without laser emission (control) | Air stimulus | −0.18 | −2.3% | No |
| G 2: Er,Cr:YSGG (0.25W, 4.4 J/cm2) | −4.89 | −61.8% | |||||||
| G 3: Er,Cr:YSGG (0.5W, 8.9J/cm2) | −6.41 | −81.5% | |||||||
Abbreviations: PD, parallel study design; SM, split mouth study design; NR, not reported.
Er,Cr,YSGG Laser Parameters in the Included Studies
| Author/Year | Power (W) | Frequency (Hz) | Pulse Duration (μs) | Energy Density (J/cm2) | Tip Size | Water | Air | Application Time |
|---|---|---|---|---|---|---|---|---|
| Moeintaghavi et al | Two applications 15 min apart 0.25 W & 0.5 W | 25 Hz | 140 μs | – | MZ6 sapphire | No | No | Each application 10s |
| Aranha and de Paula Eduardo | G3: 0.25 W | 20 Hz | 140–200 μs | 4.4 | MZ6 sapphire | No | No | 30 s |
| G4: 0.5 W | 8.9 | |||||||
| Ozlem et al | 0.25 W | 20 Hz | – | 44.3 | Z6 sapphire | No | No | 30 s |
| Pourshahidi et al | 0.25 W | 50 Hz | 140 μs | 4.4 | – | No | No | 1 min |
| Yilmaz et al | 0.25 W | 20 Hz | – | 4.4 | MZ6 sapphire | No | 10% | 30 s |
| Yilmaz et al | 0.25 W | 20 Hz | 140 μs | 4.4 | MZ6 sapphire | No | 10% | 30 s |
| Yilmaz and Bayindir | G1: 0.25 W | 20 Hz | 140 μs | 4.4 | MZ6 sapphire | No | 10% | 30 s |
| G2: 0.5 W | 8.9 |
Results of the Cochrane Risk of Bias Assessment of the Included RCTs
| Domain | Moeintaghavi et al | Aranha and de Paula Eduardo | Ozlem et al | Pourshahidi et al | Yilmaz et al | Yilmaz et al | Yilmaz and Bayindir |
|---|---|---|---|---|---|---|---|
| Low | Low | Low | Low | Low | Low | Low | |
| Domain 2: Risk of bias due to deviations from the intended interventions | Low | Low | Low | Low | Low | Low | Low |
| Domain 3: Missing outcome data | Low | Low | Low | Low | Low | Low | Low |
| Domain 4: Risk of bias in measurement of the outcome | Low | Low | Low | Low | Low | Low | Low |
| Domain 5: Risk of bias in selection of the reported result | Low | Low | Low | Low | Low | Low | Low |
Notes: Cochrane risk of bias assessment table adapted from: Sterne JAC, Elbers RG, Page MJ, et al. Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions. Hoboken: John Wiley & Sons; 2019.19 Copyright © 2019 The Cochrane Collaboration.